Literature DB >> 11562625

A single dose of nebulized budesonide decreases exhaled nitric oxide in children with acute asthma.

Y G Tsai1, M Y Lee, K D Yang, D M Chu, Y S Yuh, C H Hung.   

Abstract

This study was conducted to investigate whether a single dose of nebulized budesonide effectively decreased airway inflammation as demonstrated by exhaled nitric oxide (eNO) levels. A single dose of nebulized budesonide, but not nebulized terbutaline, rapidly decreased eNO levels in 6 hours. The decrease in eNO levels induced by nebulized budesonide was correlated to an increase in peak expiratory flow rate.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11562625     DOI： 10.1067/mpd.2001.116295

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  5 in total

1.  Exhaled nitric oxide levels during treatment of pediatric acute asthma exacerbations and association with the need for hospitalization.

Authors:  Kyle A Nelson; Pearlene Lee; Kathryn Trinkaus; Robert C Strunk
Journal:  Pediatr Emerg Care       Date:  2011-04       Impact factor: 1.454

Review 2.  Expert consensus on nebulization therapy in pre-hospital and in-hospital emergency care.

Authors: 
Journal:  Ann Transl Med       Date:  2019-09

Review 3.  Early use of inhaled corticosteroids in the emergency department treatment of acute asthma.

Authors:  Marcia L Edmonds; Stephen J Milan; Carlos A Camargo; Charles V Pollack; Brian H Rowe
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Effect of elevated exhaled nitric oxide levels on the risk of respiratory tract illness in preschool-aged children with moderate-to-severe intermittent wheezing.

Authors:  Avraham Beigelman; David T Mauger; Brenda R Phillips; Robert S Zeiger; Lynn M Taussig; Robert C Strunk; Leonard B Bacharier
Journal:  Ann Allergy Asthma Immunol       Date:  2009-08       Impact factor: 6.347

5.  A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid.

Authors:  Olof Selroos
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.